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Abstract
Genome-wide gene expression was comparatively investigated
in early-passage rheumatoid arthritis (RA) and osteoarthritis
(OA) synovial fibroblasts (SFBs; n  = 6 each) using
oligonucleotide microarrays; mRNA/protein data were validated
by quantitative PCR (qPCR) and western blotting and
immunohistochemistry, respectively. Gene set enrichment
analysis (GSEA) of the microarray data suggested constitutive
upregulation of components of the transforming growth factor
(TGF)-β pathway in RA SFBs, with 2 hits in the top 30 regulated
pathways. The growth factor TGF-β1, its receptor TGFBR1, the
TGF-β binding proteins LTBP1/2, the TGF-β-releasing
thrombospondin 1 (THBS1), the negative effector SkiL, and the
smad-associated molecule SARA were upregulated in RA SFBs
compared to OA SFBs, whereas TGF-β2 was downregulated.
Upregulation of TGF-β1 and THBS1 mRNA (both positively
correlated with clinical markers of disease activity/severity) and
downregulation of TGF-β2 mRNA in RA SFBs were confirmed
by qPCR. TGFBR1 mRNA (only numerically upregulated in RA
SFBs) and SkiL mRNA were not differentially expressed. At the
protein level, TGF-β1 showed a slightly higher expression, and
the signal-transducing TGFBR1 and the TGF-β-activating
THBS1 a significantly higher expression in RA SFBs than in OA
SFBs. Consistent with the upregulated TGF-β pathway in RA
SFBs, stimulation with TGF-β1 resulted in a significantly
enhanced expression of matrix-metalloproteinase (MMP)-11
mRNA and protein in RA SFBs, but not in OA SFBs. In
conclusion, RA SFBs show broad, constitutive alterations of the
TGF-β pathway. The abundance of TGF-β, in conjunction with
an augmented mRNA and/or protein expression of TGF-β-
releasing THBS1 and TGFBR1, suggests a pathogenetic role of
TGF-β-induced effects on SFBs in RA, for example, the
augmentation of MMP-mediated matrix degradation/remodeling.
Introduction
Human rheumatoid arthritis (RA) is characterized by chronic
inflammation and destruction of multiple joints, perpetuated by
an invasive pannus tissue. Activated synovial fibroblasts
(SFBs), whether irreversibly altered [1] or reversibly stimulated
by the inflammatory microenvironment [2], are major compo-
nents of the pannus and contribute to joint destruction by
secretion of pro-inflammatory cytokines and tissue-degrading
enzymes [3].
Recently, microarray techniques employing hybridization of
biological samples to immobilized cDNA probes or oligonucle-
otide probe sets (for example, Affymetrix®) have been increas-
ingly used to study genome-wide gene expression profiles and
to perform initial screening for genes of potential pathogenetic
interest. In the meantime, there are some studies available of
differential gene expression between RA and osteoarthritis
(OA) synovial membranes (SMs) [4-6], RA and OA SFBs [7]
or about the effects of mediators with a central role in RA, for
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rheumatoid arthritis; SFB = synovial fibroblast; SM = synovial membrane; TGF-β = transforming growth factor beta; TGFBR = TGF-β receptor; THBS 
= thrombospondin.Arthritis Research & Therapy    Vol 9 No 3    Pohlers et al.
Page 2 of 11
(page number not for citation purposes)
example, tumor necrosis factor-α and IL-1β, on SFBs [8-10].
In order to identify sets of constitutively regulated genes that
can be classified into well-known pathways, differential gene
expression between early passage RA and OA SFBs was
investigated using Affymetrix® oligonucleotide arrays and ana-
lyzed using the Gene Set Enrichment Analysis (GSEA) tool
[11]. The differential expression of such pathway components
in RA and OA SFBs may then indicate a more pronounced
potency for further activation by the respective cytokines or
growth factors, for example, transforming growth factor (TGF)-
β. To enhance the significance of the array analysis, the mRNA
data of the most important molecules were validated by real-
time reverse transcriptase (RT)-PCR and the respective pro-
teins were analyzed by western blots or immunohistochemis-
try. In addition, stimulation of SFBs with TGF-β1 was
performed to prove the functional relevance of the enhanced
expression of TGF-β pathway-related molecules in RA.
Materials and methods
Patients and samples
Synovial tissue was obtained from open joint replacement sur-
gery or arthroscopic synovectomy at the Clinic of Orthoped-
ics, Waldkrankenhaus "Rudolf Elle" (Eisenberg, Germany).
Patients with RA or OA (n = 6 each for gene expression anal-
ysis and further patients for validation experiments; total of 7
RA and 9 OA patients) were classified according to the Amer-
ican Rheumatology Association (ARA, now American College
of Rheumatology (ACR)) criteria [12] (Table 1). SFBs were
purified from synovial tissue as previously published [13].
Briefly, the tissue samples were minced, digested with trypsin/
collagenase P, and the resulting single cell suspension cul-
tured for seven days. Non-adherent cells were removed by
medium exchange. SFBs were then negatively purified using
Dynabeads® M-450 CD14 and subsequently cultured over 2
passages in DMEM containing 100 μg/ml gentamycin, 100
μg/ml penicillin/streptomycin, 20 mM HEPES and 10% FCS
(all from PAA Laboratories, Cölbe, Germany).
Culturing of cells and isolation of total RNA
At the end of the 2nd passage, the SFBs were starved with
medium containing 1% FCS for 72 h to minimize stimulating
effects by serum components. After washing with PBS, the
cells were lysed with RLT buffer (Qiagen, Hilden, Germany)
Table 1
Clinical data of patients
Patient Gender/age
(years)
Disease duration
(years)
RF ESR
(mm/h)
CRP
(mg/ml)
No. of ARA criteria Concurrent treatment
Rheumatoid arthritis
EB 73 M/68 8 + 90 48.1 6 MTX
EB 74 F/71 17 + 45 26.9 6 NSAIDs
EB 87 F/65 12 + 50 106.7 5 NSAIDs
EB 88 F/62 10 + 90 169.5 6 NSAIDs
EB 96 M/67 4 + 68 75.7 4 NSAIDs
EB 108 F/72 45 + 70 70.7 7 NSAIDs, steroids
EB 141 F/73 1 + 57 14.3 5 NSAIDs, steroids
Osteoarthritis
EB 77 F/66 5 - 2 <5.0 0 None
EB 81 F/56 3 - 14 <5.0 0 None
EB 90 F/61 2 - 18 <5.0 0 None
EB 102 F/73 8 - 20 <5.0 0 NSAIDs
EB 115 F/56 3 - 11 8.2 0 NSAIDs
EB 118 M/72 2 - 4 9.3 0 NSAIDs
EB 135 M/57 4 - 12 <5.0 0 NSAIDs
EB 165 F/63 3 - 11 6.1 0 NSAIDs
EB 172 M/61 3 - 5 <5.0 0 NSAIDs
ARA, American Rheumatism Association (now American College of Rheumatology); CRP, C-reactive protein (normal range <5 mg/l); ESR, 
erythrocyte sedimentation rate; F, female; M, male; MTX, methotrexate; NSAIDs, non steroidal anti-inflammatory drugs; RF, rheumatoid factor; -, 
negative; +, positive.Available online http://arthritis-research.com/content/9/3/R59
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and frozen at -70°C. Total RNA was isolated using the RNeasy
Kit (Qiagen) according to the supplier's recommendation.
Microarray data analysis
RNA probes were labeled according to the supplier's instruc-
tions (Affymetrix®, Santa Clara, CA, USA). Analysis of gene
expression was carried out using U95A oligonucleotide
arrays. Hybridization and washing of gene chips was per-
formed according to the supplier's instructions and microar-
rays were analyzed by laser scanning (Hewlett-Packard Gene
Scanner). Background-corrected signal intensities were
determined using the MAS 5.0 software (Affymetrix®). Subse-
quently, signal intensities were normalized among arrays to
facilitate comparisons between different patients. For this pur-
pose, arrays were grouped according to patient groups (OA
versus RA, n = 6 each). The arrays in each group were normal-
ized using quantile normalization [14]. Original data from
microarray analysis have been deposited in NCBIs Gene
Expression Omnibus [15] and are accessible through GEO
series accession number GSE7669.
Gene set enrichment analysis
GSEA was performed using the software described in [11].
Briefly, GSEA searches for the enrichment of up- or downreg-
ulated genes in pre-defined pathways and subsequently per-
forms a correction for multiple-hypotheses testing. Pathways
were ranked with respect to the score values (normalized
enrichment scores), which indicate differential expression.
GSEA was run with default settings by performing 500 ran-
dom mutations for the determination of statistical significance.
The pre-defined pathways contained two variants of the TGF-
β pathway (called 'TGF_Beta_Signaling_Pathway' and 'tgfb-
Pathway'). Both pathways were among the top 30 ranking
pathways (out of 259). A merged pathway was created by
combining the genes from the two pre-defined pathways
(TGF_joint) and GSEA was re-run including this new pathway.
Quantitative real-time PCR analysis
cDNA was prepared from total RNA using oligo-dT primers
and SuperScript reverse transcriptase (Invitrogen, Karlsruhe,
Germany). For the genes of interest and the housekeeping
aldolase gene, specific mRNA sequences were cloned using
the TOPO-TA cloning kit (Invitrogen) and employed for the
generation of external standard curves. Real-time PCR was
performed on a LightCycler® (Roche Diagnostics, Mannheim,
Germany) using LightCycler® FastStart DNA Master SYBR
Green I (Roche) as previously described [16] with the primer
pairs presented in Table 2. The amount of cDNA in each sam-
ple was normalized using the expression of the housekeeping
aldolase gene, which showed the lowest variability over all oli-
gonucleotide arrays. The general amplification protocol (50
cycles) was set as follows: initial denaturation for 3 minutes at
95°C; denaturation for 5 s at 95°C; specific primer annealing
temperature for 10 s; amplification at 72°C for the indicated
time period (Table 2). The general settings for the melting
curve protocol (1 cycle) were as follows: denaturation at
95°C; cooling to 5°C above the primer annealing temperature;
heating to 95°C (speed 0.1°C/s); final cooling for 5 minutes at
40°C. The fluorescence emitted by double-stranded DNA-
bound SYBR-Green was measured once at the end of each
additional heating step and continuously during the melting
curve program. The concentrations of cDNA present in each
sample were calculated by the LightCycler®-software using
the external standard curves. Product specificity was con-
firmed by melting curve analysis and initial cycle sequencing of
the PCR products.
Western blotting
SFBs from RA patients (n = 6 for TGF-β1; n = 5 for TGF-β
receptor (TGFBR)) and OA patients (n = 4) were cultured and
starved as above. Cell lysis was performed after washing with
PBS using NP-40 lysis buffer (50 mM Tris/HCl, pH 7.4, 150
mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM phenylmethylsulfo-
Table 2
Primer and product sizes of real-time PCR validated genes
Gene product Forward primer (5'→3') Reverse primer (5'→3') Size (bp) TA/tamp
Aldolase TCATCCTCTTCCATgAGACACTCTA ATTCTgCTggCAgATACTggCATAA 314 58°C/30 s
TGF-β1 gTTCAAgCAgAGTACACACAgC gTATTTCTggTACAgCTCCACg 157 60°C/20 s
TGF-β2 ATgCggCCTATTgCTTTAgA TAAgCTCAggACCCTgCTgT 185 60°C/20 s
TGF-β3 CAgggAgAAAATCCAggTCA CCTggAAggCgTCTAACCAAg 179 58°C/20 s
THBS1 gATCCTggACTCgCTgTAgg CCgAgTATCCCTgAgCCCTC 202 60°C/20 s
TGFBR1 ATCACCTggCCTTggTCCTgTgg GgTCCTCTTCATTTggCACTCgATg 140 54°C/20 s
SkiL CAgTggAAACTgATggAgAgC ggAAgAggCAgAAATACAgTAgg 193 55°C/20 s
MMP-11 ggTgTACgACggTgAAAAgCC CAgggTCAAACTTCCAgTAgAgg 353 64°C/30 s
Bp, base-pairs; TA, annealing temperature; tampl, amplification time.Arthritis Research & Therapy    Vol 9 No 3    Pohlers et al.
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nylfluoride (PMSF), 1 mM Na3VO4, as well as 1 μg/ml of apro-
tinin, leupeptin, and pepstatin). The protein content was
determined using the BCA assay (Pierce, Rockford, IL, USA)
following acetone precipitation of a 25 μl sample aliquot. Pro-
teins were resolved by reducing SDS-PAGE of 40 μg lysate
and subsequently detected by immunoblotting, using the fol-
lowing primary antibodies: anti-TGF-β1 (A75-2, BD Bio-
sciences, Heidelberg, Germany), anti-TGFBR 1 (#3712,
CellSignal, Beverly, MA, USA), as well as goat anti-mouse IgG
horseradish peroxidase (HRP; A-3682, Sigma-Aldrich, Stein-
heim, Germany) or goat anti-rabbit IgG HRP (sc-2004, St
Cruz Biotechnology, Heidelberg, Germany) as secondary anti-
bodies. The blots were then stripped and re-probed with
mouse anti-human β-actin (clone AC-15, Sigma-Aldrich,
Deisenhofen, Germany) and goat anti-mouse IgG HRP to
ensure equal loading. In the case of TGF-β1, attempts to quan-
tify protein levels by ELISA in the supernatants of cultured
SFBs were not successful, possibly due to its association with
the extracellular matrix surrounding the cells.
Immunohistochemistry
SFBs from RA and OA patients (n = 3 each) were cultured
and starved in chamber slides (104 cells per well) as above.
After washing with PBS and fixing in 10% formalin in PBS for
10 minutes, the antigen was unmasked by treating the cells
with citrate buffer (10 mM; pH 6.0 with NaOH, 0.05%
Tween20) and heating for 5 minutes in a microwave oven (300
W). After cooling and washing with PBS, the slides were
blocked with 5% goat serum in PBS for 30 minutes, followed
by incubation for 30 minutes with the primary antibody (mouse
anti-human thrombospondin (THBS)1, clone A6.1, LabVision
c/o Dunn Labortechnik, Asbach, Germany) diluted at 4 μg/ml
in 1% goat serum. HRP-conjugated rabbit anti-mouse IgG (in
PBS/1% goat serum) was added for 30 minutes. The peroxi-
dase was revealed using diaminobenzidine for 5 minutes, and
the slides were washed and covered with Aquatex (Merck,
Darmstadt, Germany). A mouse IgG1 monoclonal antibody
(MOPC21, Sigma; 4 μg/ml) served as control and yielded
negative results. Positively stained cells were scored semi-
quantitatively by two observers (DP and RWK) in a blinded
manner (0 = no; 1 = weak; 2 = medium; 3 = strong staining).
Stimulation with TGF-β1
SFBs from RA patients (n = 3) and OA patients (n = 4) were
cultured and starved as above. Recombinant human TGF-β1
(Peprotech, London, UK) was added at 10 ng/ml for 4 h. After
washing and lysing, RNA isolation, cDNA synthesis, and quan-
titative real-time PCR (qPCR) for aldolase and matrix-metallo-
proteinase (MMP)-11 were performed as described above.
Protein expression of MMP-11 was assessed by intracellular
staining of stimulated cells (10 ng/ml TGF-β1, 48 h) by flow
cytometry on a FACScan cytometer (BD, Heidelberg, Ger-
many). The cells were trypsinized, washed with PBS/1% FCS
and fixed with 4% paraformaldehyde in PBS for 15 minutes at
4°C. After permeabilization with 0.5% saponin in PBS/1%
FCS, the cells were incubated with anti-human-MMP-11 anti-
body (clone 135421, R&D Systems, Wiesbaden, Germany),
followed by goat anti-mouse IgG FITC (Dako, Hamburg, Ger-
many). A mouse-anti-keyhole limpet hemocyanin (KLH) anti-
body (IgG2b, clone 20116, R&D Systems) served as isotype
control.
Statistical analysis
The non-parametric Mann-Whitney U test was applied for the
comparison of differences between RA and OA in qPCR,
western blots, immunohistochemistry, and flow cytometry
assays. Statistically significant differences were accepted for
p ≤ 0.05. For correlations between gene expression and clini-
cal parameters, the Spearman Rank Test was used (p ≤ 0.01).
Results
Comparison of constitutive gene expression in RA and 
OA SFB by GSEA
Gene expression in early passage SFBs derived from SM of 6
RA patients was compared to that in SFBs from SM of 6 OA
patients. The GSEA software was used to evaluate the gene
expression values and to classify the data into various
pathways depending on the augmented expression of path-
way-related genes. Out of 259 pathways, 96 pathways were
upregulated and 163 pathways were downregulated in RA
SFBs compared to OA SFBs. The
TGF_Beta_Signaling_Pathway was ranked sixth after five other
pathways (for example, Inflammatory_Response_Pathway,
CR_Immune_Function, IL7_Pathway) for upregulation in RA
SFBs (Table 3). Another variant of the TGF-β pathway was also
among the top 30 pathways (26th place), as was the 'joint
pathway' (TGF_joint, 8th place), which was created by merg-
ing the genes from the two pathways (see Materials and meth-
ods). In addition, GSEA was applied to compare the gene
expression values of OA and RA SFBs and to score each gene
according to the mean value in the respective group. Marginal
differences were excluded by considering only scores higher
than 0.4 or less than -0.4. Positive values indicate lower
expression in RA SFBs, and negative values show more pro-
nounced expression in RA SFBs. For the TGF-β pathway, the
most important components are selected and listed in Table 4.
The function of the molecules within the pathway in conjunc-
tion with their scores is demonstrated in Figure 1.
The mRNA for TGF-β1 and TGF-β3, TGFBR1, the latent TGF-
β binding proteins 1/2 (LTBP1/2), the TGF-β-releasing
THBS1, the TGF-β induced factor 2 (TGIF2), the CREB bind-
ing protein (CREBBP), the SKI-like protein (SKIL), as well as
the smad-associated molecule SARA (smad anchor of recep-
tor activation; ZFYVE9) were upregulated in RA SFBs when
compared to OA SFBs, with scores between -0.48 and -1.108
(Table 4). Interestingly, a positive score was observed for
TGF-β2 (0.521), indicating augmented expression in OA
SFBs compared to RA SFBs.Available online http://arthritis-research.com/content/9/3/R59
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Quantitative PCR analyses of differentially expressed 
genes
To validate the results of the array analysis, differentially
expressed genes of the TGF-β pathway were analyzed by
independent qPCR. A significantly higher, constitutive expres-
sion of TGF-β1 (Figure 2a) and a significantly lower expression
of TGF-β2 (Figure 2b) in RA SFBs versus OA SFBs was con-
firmed by qPCR. In contrast to the array data, the mRNA for
TGF-β3 was significantly downregulated in RA SFBs. How-
ever, as in the case of TGF-β2, the relative levels of TGF-β3
(0.0001 to 0.002) were generally low compared to those of
TGF-β1 (0.02 to 0.04).
The upregulation of TGF-β1 mRNA was accompanied by sig-
nificantly higher expression of the TGF-β-releasing factor
THBS1 in RA SFBs versus OA SFBs (Figure 2e). The consti-
tutively increased expression of the TGFBR1 (only numerically
increased) and the SkiL gene by RA SFBs in comparison to
OA SFBs was not confirmed by qPCR (Figure 2d,f).
Protein expression of TGF-β pathway-related molecules
To further validate the constitutive elevation of the TGF-β path-
way in early passage RA SFBs, the translation of mRNA into
proteins was analyzed in SFBs from additional OA and RA
patients by western blots for TGF-β1 and TGFBR1, as well as
immunohistochemistry staining for THBS1.
In contrast to the mRNA expression data by array hybridization
and real-time PCR data, the protein for TGF-β1 was only
numerically increased in RA SFBs (Figure 3). The protein lev-
els of TGFBR1, the receptor that transduces the signal into
the cell after binding of TGF-β (Figure 1), were significantly
upregulated in RA SFBs compared to OA SFBs (Figure 4; blot
and quantification).
The protein expression of THBS1, known to activate TGF-β by
releasing it from the latent form, was investigated by immuno-
histochemistry and semi-quantitative scoring methods. Cul-
tured RA SFBs showed a significantly stronger staining for
THBS1 (2.33 ± 0.33 (mean ± standard error of the mean))
than OA SFBs (0.66 ± 0.33; p = 0.02). Representative stain-
ing for THBS1 and the respective isotype antibody in SFBs
from one patient each with RA or OA is shown in Figure 5.
Stimulation of SFBs with TGF-β1
In order to address the functional relevance of the constitu-
tively activated TGF-β pathway, SFBs from RA and OA
patients were stimulated with recombinant TGF-β1 and the
effect on gene expression for MMP-11 (stromelysin 3) was
analyzed by qPCR. A significantly enhanced MMP-11 mRNA
expression was observed 4 h after stimulation with TGF-β1 in
RA SFBs, but not in OA SFBs (Figure 6). In addition, intracel-
lular MMP-11 protein, measured as mean fluorescence inten-
sity of MMP-11 positive cells, increased in RA SFBs to
significantly higher levels than in OA SFBs (Figure 7). How-
ever, the proliferation response of SFBs to TGF-β1 was not
different (data not shown).
Correlation with clinical parameters
Analyzing RA and OA SFBs together, significant positive cor-
relations were observed between the constitutive expression
of TGF-β1 mRNA (but not protein) and the serum levels of C-
reactive protein (r = 0.711, n = 12; p = 0.01), as well as the
Table 3
Top 30 differentially regulated pathways in rheumatoid arthritis 
using Gene Set Enrichment Analysis
Rank Name Sizea NES
1 Inflammatory_Response_Pathway 42 -1.7343
2 CR_IMMUNE_FUNCTION 72 -1.4860
3 cell_motility 148 -1.3477
4 il7Pathway 37 -1.3376
5 breast_cancer_estrogen_signalling 167 -1.2575
6 TGF_Beta_Signaling_Pathway 76 -1.2538
7 p38mapkPathway 72 -1.2517
8T G F _ j o i n t 9 1 - 1 . 2 4 9 4
9 ST_Ga12_Pathway 36 -1.2444
10 P53_UP 55 -1.2301
11 SA_CASPASE_CASCADE 31 -1.2147
12 Wnt_Signaling 79 -1.2121
13 fasPathway 60 -1.1990
14 EMT_DOWN 56 -1.1655
15 CR_CAM 143 -1.1651
16 cell_adhesion 245 -1.1628
17 NFKB_REDUCED 30 -1.1577
18 mRNA_processing 55 -1.1485
19 ST_MONOCYTE_AD_PATHWAY 39 -1.1485
20 GPCRs_Class_B_Secretin-like 28 -1.1401
21 GLUCOSE_DOWN 261 -1.1364
22 tnf_and_fas_network 33 -1.1302
23 ST_Fas_Signaling_Pathway 97 -1.1263
24 shh_lisa 33 -1.1164
25 intrinsicPathway 28 -1.1160
26 tgfbPathway 35 -1.0937
27 alkPathway 57 -1.0871
28 hdacPathway 45 -1.0860
29 41bbPathway 33 -1.0787
30 ST_Ga13_Pathway 54 -1.0367
aSize refers to the number of included genes. NES, normalized 
enrichment scoresArthritis Research & Therapy    Vol 9 No 3    Pohlers et al.
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number of fulfilled American Rheumatism Association (now
American College of Rheumatology) criteria (r = 0.726, n =
12; p = 0.007). The latter also correlated significantly with the
constitutive THBS1 mRNA expression (r = 0.726, n = 12; p =
0.007).
Discussion
The aim of the present study was to systemically analyze dif-
ferentially expressed pathways in purified, early passage SFBs
derived from RA and OA patients. For this purpose, gene
expression was measured with oligonucleotide array technol-
ogy and validated by other, low-throughput methods.
SFBs showed a differential, constitutive expression of genes
involved in various cellular pathways (Table 3). Using the soft-
ware tool GSEA for pathway scanning [11], components of
the TGF-β pathway were found to be over-represented among
these genes. As well as TGF-β1 and its receptor TGFBRI, the
following molecules were also upregulated in RA SFBs:
LTBP1 and LTBP2, both components of the large latent TGF-
β complex binding TGF-β to the extracellular matrix [17];
THBS1, known to release active TGF-β from its latent form
[18]; and SARA, which recruits the TGF-β-signal-transducing
smads to the membrane in the close vicinity of the receptor
[19] (Figure 1). This interesting finding provides detailed anal-
ysis of individual components of the TGF-β pathway and
parallels recent reports on the existence of two distinct gene
expression profiles in SFBs, one of which is characterized by
the expression of TGF-β/activin A-inducible genes [7].
Although hierarchical clustering of the data in the present
study did not reveal such distinct profiles in purified SFBs
(data not shown; possibly due to the low number of samples),
the overexpression of TGF-β-related genes supports the
importance of this pathway in synovial pathology. This is fur-
ther underlined by significant correlations between the consti-
tutive TGF-β1 and THBS1 mRNA expression in SFBs and the
C-reactive protein levels or the number of fulfilled ARA criteria,
that is, clinical markers of disease activity and/or severity.
TGF-β1 mRNA was expressed to a significantly higher degree
in RA SFBs than OA SFBs, in parallel with previous reports
showing a significantly higher expression of TGF-β1 in the RA
SM than in the OA SM [20-22]. Specific assignment of TGF-
β1 production to fibroblast-like synoviocytes in the RA SM
[21] or to fibroblasts in synovial regions with pronounced
fibrosis provides evidence for a pro-fibrotic role of TGF-β1 in
RA [22]. Also, the expression of TGF-β1 directly at the carti-
lage-pannus junction during the most severe phase of rat col-
lagen-induced arthritis [23] suggests TGF-β1 has an
important pro-destructive role in experimental arthritis.
The observed discrepancy between the expression of TGF-β1
mRNA and protein in SFBs may be due to the fact that blot
analysis with the present monoclonal antibody underestimates
the total amount of protein by detecting only the active form of
TGF-β1. In fact, newly synthesized TGF-β1 is predominantly
secreted as the latent proform, as also observed in irradiated
rat mesangial cells [24]. On the other hand, known post-tran-
scriptional regulation of the TGF-β1 gene via the 5' untrans-
lated region may prevent its proportional translation into
protein [25]. Secretion of TGF-β1 into the supernatant of the
cells was excluded as a possible reason for the observed dis-
crepancy, since no signal was obtained by ELISA.
In contrast to the levels of TGF-β1 mRNA (upregulated in RA
SFBs), the amounts of TGF-β2 and TGF-β3 mRNA, which
Table 4
GSEA scores of differentially regulated genes of the TGF-β pathway
Probe set Gene symbola Gene namea Scoreb
1262_s_at/971_s_at TGFB2 Transforming growth factor, beta 2 0.521/0.404
1865_at SKIL SKI-like -0.480
1830_s_at/1634_s_at TGFB1 Transforming growth factor, beta 1 -0.529/-0.537
1866_g_at SKIL SKI-like -0.531
38889_at ZFYVE9 Zinc finger, FYVE domain containing 9 (SARA) -0.538
33831_at CREBBP CREB binding protein, CBP -0.539
38311_at TGIF2 TGFB-induced factor 2 -0.559
1734_at TGFB3 Transforming growth factor, beta 3 -0.618
1495_at LTBP1 Latent TGFB binding protein 1 -0.719
37906_at LTBP2 Latent TGFB binding protein 2 -0.751
1957_s_at/32903_at TGFBR1 Transforming growth factor, beta receptor I -0.778/-0.851
867_s_at/866_at/115_at THBS1 Thrombospondin 1 -0.936/-1.104/-1.108
aOfficial gene symbol and gene name approved by the HUGO Gene Nomenclature Committee (HGNC). bCalculated by Gene Set Enrichment 
Analysis (GSEA) software from the mean expression value.Available online http://arthritis-research.com/content/9/3/R59
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Figure 1
Central components of the transforming growth factor (TGF)-β pathway are shown with their scores, as determined by Gene Set Enrichment Analy- sis of the oligonucleotide microarray data Central components of the transforming growth factor (TGF)-β pathway are shown with their scores, as determined by Gene Set Enrichment Analy-
sis of the oligonucleotide microarray data. Molecules upregulated in synovial fibroblast (SFBs) from rheumatoid arthritis patients are shown in red 
(negative values), and those upregulated in osteoarthritis SFBs are shown in green (positive values). Red arrow indicates the cleavage site. CBP, 
CREB binding protein; LAP, latency-associated protein; LTBP, latent TGF-β binding protein; P, phosphate; TGFBR, TGF-β receptor; TGIF, TGFB-
induced factor; THBS, thrombospondin.Arthritis Research & Therapy    Vol 9 No 3    Pohlers et al.
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share the same receptors, were significantly increased in OA
SFBs by qPCR. This is in agreement with results showing on
the one hand predominant effects of TGF-β2/3 versus TGF-β1
in an age model of OA [26], but on the other hand a strong
immunoreactivity at the protein level only for TGF-β1 but not
for TGF-β2/3 in the RA SM [27]. In addition, there is strong
evidence that the isoforms have different functions, as demon-
strated by the non-overlapping phenotypes of the isoform-spe-
cific null mice [27]. Together, these findings argue for a pivotal
and differential role of TGF-β1 in the pathogenesis of RA.
In addition to TGF-β itself, its receptor TGFBRI was upregu-
lated in RA SFBs, providing the basis for an enhanced
autocrine effect of locally present TGF-β1 on SFBs in the RA
SM. Whereas this study provides the first report concerning
the expression of TGFBR1 in human arthritis, the type II recep-
tor [22] and endoglin (a receptor for TGF-β1 and 3) [20] have
been reported to be more strongly expressed in RA SM than
in OA SM or normal SM, showing the relevance of TGF-β-sig-
naling in RA.
The present study shows a constitutive upregulation of
THBS1 (mRNA/protein) in RA SFBs. A constitutively higher
expression of THBS1 has previously been described in RA
synovium compared to OA and joint trauma [28] and the syn-
ovial expression of this molecule has been assigned to
endothelial cells, macrophages and synovial lining cells [29].
Furthermore, it has been demonstrated that implantation of
THBS1-containing pellets into the ankle joints of rats aggra-
vates adjuvant arthritis [30], showing the importance of
THBS1 in arthritis. TGF-β is initially produced in its latent form
[31,32], that is, covalently linked with the latency-associated
proteins and attached to LTBPs, which are cross-linked to the
extracellular matrix (reviewed in [17]). In order to activate TGF-
β, the mature molecule has to be released from the large latent
complex by plasmin or cathepsins [33] or, as previously
described, with a high efficiency by THBS1 [18]. The abun-
dance of THBS1 may, therefore, lead to enhanced activation
of latent TGF-β1 in RA (see above), resulting in more TGF-β1
activity in the arthritic joint. Indeed, increased levels of active
TGF-β1 have recently been reported in RA synovial fluid in
Figure 2
mRNA-expression of the transforming growth factor (TGF)-β related genes mRNA-expression of the transforming growth factor (TGF)-β related genes: (a) TGF-β1, (b) TGF-β2, (c) TGF-β3, (d) TGF-β receptor 1 (TGFBR1), 
(e) thrombospondin 1 (THBS1), and (f) skiL in osteoarthritis (OA) synovial fibroblast (SFBs) and rheumatoid arthritis (RA) SFBs (n = 6 each), as 
assessed by quantitative real-time PCR. Bars indicate the medians ± 75th and 25th percentiles relative to the expression of aldolase. *p ≤ 0.05 com-
pared to OA.Available online http://arthritis-research.com/content/9/3/R59
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Figure 3
Transforming growth factor (TGF)-β1 protein expression in osteoarthri- tis (OA) synovial fibroblast (SFBs) (n = 4) and rheumatoid arthritis (RA)  SFBs (n = 6), as assessed by SDS-PAGE/western blotting Transforming growth factor (TGF)-β1 protein expression in osteoarthri-
tis (OA) synovial fibroblast (SFBs) (n = 4) and rheumatoid arthritis (RA) 
SFBs (n = 6), as assessed by SDS-PAGE/western blotting. Bars indi-
cate the optical density of the protein bands (median ± 75th and 25th 
percentiles) relative to the β-actin control.
Figure 4
TGF-β receptor 1 (TGFBR1) and β-actin (control) protein expression in  osteoarthritis (OA) synovial fibroblast (SFBs) (n = 4) and rheumatoid  arthritis (RA) SFBs (n = 5) as assessed by SDS-PAGE/western blot- ting (upper panel) TGF-β receptor 1 (TGFBR1) and β-actin (control) protein expression in 
osteoarthritis (OA) synovial fibroblast (SFBs) (n = 4) and rheumatoid 
arthritis (RA) SFBs (n = 5) as assessed by SDS-PAGE/western blot-
ting (upper panel). Bars indicate the median optical density of protein 
bands ± 75th and 25th percentiles relative to the value of the β-actin 
bands (lower panel). *p ≤ 0.05 compared to OA.
Figure 5
Protein expression of thrombospondin 1 (THBS1) in (a) rheumatoid  arthritis (RA) synovial fibroblast (SFBs) and osteoarthritis SFBs (b), as  assessed by immunohistochemistry Protein expression of thrombospondin 1 (THBS1) in (a) rheumatoid 
arthritis (RA) synovial fibroblast (SFBs) and osteoarthritis SFBs (b), as 
assessed by immunohistochemistry. Brown staining indicates the pres-
ence of THBS1 in SFBs from one representative of three RA and three 
OA patients; nuclei are counterstained in blue (hematoxylin). The 
respective staining with an isotype control instead of the specific pri-
mary antibody is demonstrated in the insert; the magnification scale is 
shown in (a).
Figure 6
Transforming growth factor (TGF)-β1-stimulated mRNA expression for  matrix-metalloprotease (MMP)-11 in osteoarthritis (OA) synovial fibro- blast (SFBs) (n = 4) and rheumatoid arthritis (RA) SFBs (n = 3), as  assessed by qPCR Transforming growth factor (TGF)-β1-stimulated mRNA expression for 
matrix-metalloprotease (MMP)-11 in osteoarthritis (OA) synovial fibro-
blast (SFBs) (n = 4) and rheumatoid arthritis (RA) SFBs (n = 3), as 
assessed by qPCR. Bars indicate the medians ± 75th and 25th per-
centiles relative to the expression of aldolase, expressed as percent of 
the unstimulated control (= 100%). *p ≤ 0.05 compared to OA.Arthritis Research & Therapy    Vol 9 No 3    Pohlers et al.
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comparison to OA synovial fluid [34]. This TGF-β1 activity may
then contribute to enhanced proliferation of SFBs [35] or
enhanced production of MMPs [36].
In the present study, the induction of MMP-11 (stromelysin-3)
at the mRNA and protein levels by TGF-β1 was restricted to
RA SFBs. This effect has been originally described for mouse
fibroblasts and osteoblasts and was based on both stimulation
of gene transcription and stabilization of mRNA transcripts
[37]. The rapid upregulation of mRNA after 4 h suggests a
direct activation of gene transcription rather than an indirect
induction via other factors, that is, platelet-derived growth fac-
tor [38], which is also a known inducer of MMP-11 [39]. Like
other MMPs, MMP-11 requires proteolytic removal of propep-
tides for activation. Whereas for other MMPs this process
occurs via extracellular proteases following secretion, MMP-
11 is intracellularly processed by furin and secreted as an
active protease (in analogy to membrane-type MMP) [40].
Therefore, the presence of increased intracellular levels
observed in the present study represents the basis for func-
tional MMP-11 outside the cell. Although MMP-11 does not
directly participate in the degradation of extracellular matrix, it
is able to inactivate protease inhibitors, resulting in enhanced
proteolytic activity [41] and controls cell proliferation by
processing the insulin-like growth factor-binding protein-1
[42]. MMP-11 is, therefore, involved in matrix turnover and pro-
liferation, both processes with implications for RA. Its specific
upregulation by TGF-β further supports a functional relevance
of the constitutively upregulated TGF-β pathway in RA.
Conclusion
The presence of TGF-β, in conjunction with augmented
mRNA/protein expression of the TGF-β releasing THBS1 and
higher TGFBR1 protein by RA SFBs, suggests that TGF-β-
induced effects have a (autocrine) pathogenetic importance in
RA, for example, the induction of MMP-mediated matrix
degradation/remodeling.
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